Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.53 |
| ▸ | RXRB | P28702 | 12/20 | 0.53 |
| ▸ | RXRG | P48443 | 12/20 | 0.53 |
| ▸ | RARB | P10826 | 6/20 | 0.51 |
| ▸ | RARG | P13631 | 5/20 | 0.51 |
| ▸ | RARA | P10276 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8116214 | 0.89 | RXRA (0.69) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8113512 | 0.88 | RXRA (0.56) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7709680 | 0.87 | RARB (0.59) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7710046 | 0.85 | RXRA (0.69) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7703916 | 0.85 | RARA (0.41) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8114654 | 0.84 | RXRA (0.67) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8116675 | 0.83 | RXRA (0.70) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL4368209 | 0.83 | RXRA (0.75) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8122280 | 0.80 | RXRA (0.67) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7703913 | 0.78 | RARA (0.57) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6127382-A | AN ANTIPROLIFERATIVE AGENT FOR TREATING SKIN-RELATED DISEASES, AN ANTITUMOR AGENT TREATING CANCER, AN ANTIINFLAMMATORY AGENT TREATING PULMONARY FIBROSIS, ILEITIS, COLITIS AND KROHN'S DISEASE | ALLERGAN SALES, INC. (US) | 2000-10-03 | — | — | US | disclosed |